Extracellular Matrix and Outflow Resistance
Extracellular Matrix and Outflow Resistance
批准号:
8288856
负责人:
Kate E Keller
金额:
$22.18万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-08-01 至 2015-06-30
关键词:
AffectAgingAnteriorAqueous HumorAreaAttenuatedBackBindingBiologicalBlindnessC-terminalCell surfaceCellsCellular StructuresCleaved cellComplexConfocal MicroscopyDataDevelopmentDiseaseDisintegrinsEndosomesEnzymesEventExtracellular MatrixExtracellular Matrix DegradationExtracellular SpaceEyeGenesGlaucomaGoalsHomeostasisHumanHyaluronanHyaluronidaseImmunofluorescence MicroscopyInvestigationLeadLifeMMP2 geneMatrix MetalloproteinasesMessenger RNAMetalloproteasesModelingMolecularPathway interactionsPatientsPeptide HydrolasesPerfusionPhysiologic Intraocular PressurePhysiologicalPrimary Open Angle GlaucomaProcessProteoglycanRNA InterferenceRecombinantsRecyclingResistanceReverse Transcriptase Polymerase Chain ReactionRoleSeriesSiteStructureSymptomsTestingTimeTrabecular meshwork structureWorkaqueousaqueous humor flowbasecell growth regulationcell typeextracellulargene synthesishuman MMP14 proteininhibitor/antagonistmRNA Transcript Degradationnovelpressurepublic health relevanceresponseuptakeversican
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary.
Glaucoma is a common blinding disease that affects over 66 million people worldwide and is frequently
associated with elevated intraocular pressure (IOP). However, a homeostatic mechanism to adjust elevated
IOP must exist since less than 10% of people develop glaucoma. Elevated IOP is caused by increased
resistance to aqueous humor outflow through the trabecular meshwork (TM). When TM cells are subjected to
sustained elevated IOP, they initiate remodeling of the extracellular matrix (ECM) by releasing specific
proteinases including matrix metalloproteinases (MMPs). ECM turnover produces a new, reduced resistance to
allow greater aqueous humor outflow through the TM and decrease IOP. Examination of the molecules
involved in remodeling, their proteolytic targets and modes and sites of action is critical in order for us to
understand how IOP is adjusted. Our long-term goal is to determine the molecular mechanisms by which
elevated IOP is homeostatically adjusted in normal eyes. The goal of this current proposal is to further
elucidate the function of two ECM components, ADAMTS4 and hyaluronan, and their roles in IOP
homeostasis.
ADAMTS4 (A Disintegrin and Metalloproteinase with Thrombospondin motifs) is a proteolytic enzyme
that degrades ECM components in the TM. ADAMTS4 increases outflow facility in anterior segment perfusion
culture suggesting a role for ADAMTS4 in normal homeostatic responses to elevated IOP. Here, we propose a
working model whereby ADAMTS4 is activated at specialized cellular structures, then cleaves its target
molecules and is internalized into the cell in endosomes. These endosomes may be recycled to the cell
surface to release active ADAMTS4 back into the ECM. We will investigate how ADAMTS4 is proteolytically
activated and its cellular fate following activation in TM cells. Hyaluronan concentrations in TM decrease during
aging and in POAG, which may be due to decreased synthesis, increased degradation or increased cellular
hyaluronan uptake. Recently, three genes involved in hyaluronan synthesis and six genes responsible for
hyaluronan degradation have been identified and we will investigate their mRNA levels in response to
pressure. We will also determine how decreased hyaluronan concentration affects outflow facility in anterior
segment perfusion culture. Finally, the effects of hyaluronan concentration on ADAMTS4/MMP expression,
localization and/or activation in TM cells will be determined.
Investigation into the molecular mechanisms by which ADAMTS4 and hyaluronan are regulated in the
TM will provide new information on the complex series of events that leads to homeostatic adjustment of IOP.
Studying the molecular details of normal IOP homeostasis should facilitate development of novel therapies
targeted at reducing IOP in glaucoma patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Thrombospondin-1 in normal and glaucomatous trabecular meshwork
-
批准号:10444384
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2022
-
负责人:Kate E Keller
-
依托单位:
Thrombospondin-1 in normal and glaucomatous trabecular meshwork
-
批准号:10642816
-
项目类别:
-
资助金额:$39.36万
-
财政年份:2022
-
负责人:Kate E Keller
-
依托单位:
In vivo trabecular meshwork gene expression response to elevated IOP
-
批准号:10487567
-
项目类别:
-
资助金额:$18.67万
-
财政年份:2021
-
负责人:Kate E Keller
-
依托单位:
In vivo trabecular meshwork gene expression response to elevated IOP
-
批准号:10286909
-
项目类别:
-
资助金额:$23.1万
-
财政年份:2021
-
负责人:Kate E Keller
-
依托单位:
Translational Vision Science Research at Oregon Health & Science University
-
批准号:9913537
-
项目类别:
-
资助金额:$17.22万
-
财政年份:2013
-
负责人:Kate E Keller
-
依托单位:
AI training module for Vision Science
-
批准号:10405897
-
项目类别:
-
资助金额:$8.64万
-
财政年份:2013
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:7985508
-
项目类别:
-
资助金额:$26.95万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:8678928
-
项目类别:
-
资助金额:$21.73万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:10650887
-
项目类别:
-
资助金额:$42.66万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:8116484
-
项目类别:
-
资助金额:$25.87万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular matrix and outflow resistance
-
批准号:9103960
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular matrix and outflow resistance
-
批准号:9477666
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:10208565
-
项目类别:
-
资助金额:$42.28万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:8494052
-
项目类别:
-
资助金额:$21.07万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular Matrix and Outflow Resistance
-
批准号:10404599
-
项目类别:
-
资助金额:$41.38万
-
财政年份:2010
-
负责人:Kate E Keller
-
依托单位:
Extracellular matrix and outflow resistance
-
批准号:9913533
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2009
-
负责人:Kate E Keller
-
依托单位:
海外基金